Informasjon/Twitter/Artikler/Børsmeldinger
Ny klinikk oppført på Cysview i ettermiddag.
**Blessing Health System 02.03.20
Broadway at 11th Street, PO Box 7005, Quincy, IL 62305
I tillegg er følgende oppført hittil i 2020:
**Perlmutter Cancer Center at NYU Langone Health | NYU Langone Urology Associates 27.02.20
222 East 41st Street New York, NY 10017
**Sharp Memorial Hospital 24.02.20
7901 Frost Street, San Diego, CA 92123
**Cleveland Clinic Akron 05.02.20
1 Akron General Ave., Akron, OH 44307
**University of Washington 27.01.20
1959 NE Pacific St, Seattle, WA 98195
**University of Florida Department of Urology 15.01.20
1600 SW Archer Road, Room N216, Gainesville, FL 32610
**Beth Israel Deaconess Medical Center 13.01.20
330 Brookline Ave., Rabb 440, Boston, MA 02215
**Blessing Health System 02.03.20
Broadway at 11th Street, PO Box 7005, Quincy, IL 62305
I tillegg er følgende oppført hittil i 2020:
**Perlmutter Cancer Center at NYU Langone Health | NYU Langone Urology Associates 27.02.20
222 East 41st Street New York, NY 10017
**Sharp Memorial Hospital 24.02.20
7901 Frost Street, San Diego, CA 92123
**Cleveland Clinic Akron 05.02.20
1 Akron General Ave., Akron, OH 44307
**University of Washington 27.01.20
1959 NE Pacific St, Seattle, WA 98195
**University of Florida Department of Urology 15.01.20
1600 SW Archer Road, Room N216, Gainesville, FL 32610
**Beth Israel Deaconess Medical Center 13.01.20
330 Brookline Ave., Rabb 440, Boston, MA 02215
Redigert 21.01.2021 kl 02:06
Du må logge inn for å svare
-
«
- 1
- 2 »
Detecting Invisible Bladder Cancers with Blue Light Cystoscopy - Beyond the Abstract
April 27, 2020
Blue-light cystoscopy (BLC) is a photodynamic diagnostic technique that augments the detection of occult disease missed under traditional white light. Instillation of hexaminolevulinate, a heme precursor, causes preferential accumulation of protoporphyrin IX and other photoactive porphyrins in neoplastic cells, which are then excited under the wavelength of blue light (~450 nm) to fluoresce red. The sensitivity of BLC in detecting cancerous lesions is much higher than that of white-light alone (91% vs. 76%) and used together, BLC plus WLC has a sensitivity of 98.5%.1
A recent phase III prospective multicenter study found that 20.6% of bladder malignancies were visualized solely under blue-light and would have been missed with WLC alone, consistent with other prospective BLC trials.2 Compared to standard WLC, BLC increases detection rates of papillary malignancy by 12% and CIS by 43%. In this trial, the improved detection rate and increased accuracy of risk stratification after BLC led to a change in management in 14% of patients who would have been under-staged and under-treated with WLC alone.3 The rate of false positive lesions is comparable between WLC and BLC (approximately 25-30%). In a subset of 13 patients who had recurrent high risk disease that was detected by BLC only, none had positive urine cytology, suggesting that though urinary cytology has high specificity, the sensitivity in high grade diseases may not be sufficient.
BLC has virtually no known toxic effects and patients report decreased anxiety and would recommend it to others.2,4 Following the positive data coming from large clinical trials, the addition of BLC in various settings is currently supported by the American Urological Association-Society of Urologic Oncology and the European Association of Urology.3 Expert recommendations currently support the use of BLC in post-treatment surveillance, as literature has demonstrated a survival benefit and decrease in recurrence rates with its incorporation.1,3
Our experience with this patient suggests an additional role for BLC in the initial diagnosis. There remain unanswered questions regarding the role of BLC in patients with non-muscle invasive BC at high risk for progression to invasive disease. In a recent review of the Cysview registry of over 3,500 lesions from over 1,200 patients, 23% of lesions were only visible under blue light and 14% of these lesions were muscle-invasive and would not have been detected otherwise (unpublished data). Early detection of disease is associated with a decrease in disease morbidity and mortality by increasing the utility of bladder-sparing therapies in non-muscle invasive disease and facilitating earlier delivery of neoadjuvant chemotherapy and radical cystectomy in muscle-invasive disease. This is of particular importance, considering the recurrence rate of non-muscle-invasive bladder cancer is 50-70%, and approximately 10-20% of patients will progress to muscle-invasive disease.5 Enhanced cystoscopic techniques have proven critical for earlier detection and accurate staging of both initial and recurrent cases.
Written by: Nima Nassiri, MD; Marissa Maas, BS; Kian Asanad, MD; Siamak Daneshmand, MD, Institute of Urology. Keck School of Medicine. University of Southern California. Los Angeles, CA
Disclosure: Dr. Daneshmand is a paid consultant for PhotoCure
References:
https://twitter.com/UrologyofVA/status/1255897222098673666?s=20
April 27, 2020
Blue-light cystoscopy (BLC) is a photodynamic diagnostic technique that augments the detection of occult disease missed under traditional white light. Instillation of hexaminolevulinate, a heme precursor, causes preferential accumulation of protoporphyrin IX and other photoactive porphyrins in neoplastic cells, which are then excited under the wavelength of blue light (~450 nm) to fluoresce red. The sensitivity of BLC in detecting cancerous lesions is much higher than that of white-light alone (91% vs. 76%) and used together, BLC plus WLC has a sensitivity of 98.5%.1
A recent phase III prospective multicenter study found that 20.6% of bladder malignancies were visualized solely under blue-light and would have been missed with WLC alone, consistent with other prospective BLC trials.2 Compared to standard WLC, BLC increases detection rates of papillary malignancy by 12% and CIS by 43%. In this trial, the improved detection rate and increased accuracy of risk stratification after BLC led to a change in management in 14% of patients who would have been under-staged and under-treated with WLC alone.3 The rate of false positive lesions is comparable between WLC and BLC (approximately 25-30%). In a subset of 13 patients who had recurrent high risk disease that was detected by BLC only, none had positive urine cytology, suggesting that though urinary cytology has high specificity, the sensitivity in high grade diseases may not be sufficient.
BLC has virtually no known toxic effects and patients report decreased anxiety and would recommend it to others.2,4 Following the positive data coming from large clinical trials, the addition of BLC in various settings is currently supported by the American Urological Association-Society of Urologic Oncology and the European Association of Urology.3 Expert recommendations currently support the use of BLC in post-treatment surveillance, as literature has demonstrated a survival benefit and decrease in recurrence rates with its incorporation.1,3
Our experience with this patient suggests an additional role for BLC in the initial diagnosis. There remain unanswered questions regarding the role of BLC in patients with non-muscle invasive BC at high risk for progression to invasive disease. In a recent review of the Cysview registry of over 3,500 lesions from over 1,200 patients, 23% of lesions were only visible under blue light and 14% of these lesions were muscle-invasive and would not have been detected otherwise (unpublished data). Early detection of disease is associated with a decrease in disease morbidity and mortality by increasing the utility of bladder-sparing therapies in non-muscle invasive disease and facilitating earlier delivery of neoadjuvant chemotherapy and radical cystectomy in muscle-invasive disease. This is of particular importance, considering the recurrence rate of non-muscle-invasive bladder cancer is 50-70%, and approximately 10-20% of patients will progress to muscle-invasive disease.5 Enhanced cystoscopic techniques have proven critical for earlier detection and accurate staging of both initial and recurrent cases.
Written by: Nima Nassiri, MD; Marissa Maas, BS; Kian Asanad, MD; Siamak Daneshmand, MD, Institute of Urology. Keck School of Medicine. University of Southern California. Los Angeles, CA
Disclosure: Dr. Daneshmand is a paid consultant for PhotoCure
References:
https://twitter.com/UrologyofVA/status/1255897222098673666?s=20
Redigert 30.04.2020 kl 19:08
Du må logge inn for å svare
Onsdag spiller Radforsk inn 2 podcast. Schneider og Erik Dahl fra Photocure blir med i den ene.
Kan være vel verdt å få med seg sett i lys av siste tids hendelser 😀👍
https://twitter.com/radforsk/status/1256880037086756865?s=20
Kan være vel verdt å få med seg sett i lys av siste tids hendelser 😀👍
https://twitter.com/radforsk/status/1256880037086756865?s=20
Oppdatert Topp 20 hvor det økes og endres etter emisjonen😀
NETTO økning Topp 50 forrige uke er 1,4 mill aksjer.
5.SEB LIFE INTERN ASSUR COMPANY DAC INN med 430k
14.VERDIPAPIRFONDET DELPHI NORDIC INN 255k
15.SOCIETE GENERALE PARIS INN 254k
17.VERDIPAPIRFONDET PARETO INVESTMENT INN 250k
40.ABN AMRO GLOBAL CUSTODY SERVICES INN 111k
46.AVANZA BANK AB INN 98k
47.SKANDIA NORDEN INN 96k
Følgende skyves ut av Topp 50 forrige uke:
SOCIETE GENERALE214
MORGAN STANLEY & CO. INTERNATIONAL
CITIBANK, N.A.
BURSKI KRZYSZTOF
FOLKES AS
FONDSAVANSE AS
https://photocure.com/investor/largest-shareholders/
NETTO økning Topp 50 forrige uke er 1,4 mill aksjer.
5.SEB LIFE INTERN ASSUR COMPANY DAC INN med 430k
14.VERDIPAPIRFONDET DELPHI NORDIC INN 255k
15.SOCIETE GENERALE PARIS INN 254k
17.VERDIPAPIRFONDET PARETO INVESTMENT INN 250k
40.ABN AMRO GLOBAL CUSTODY SERVICES INN 111k
46.AVANZA BANK AB INN 98k
47.SKANDIA NORDEN INN 96k
Følgende skyves ut av Topp 50 forrige uke:
SOCIETE GENERALE214
MORGAN STANLEY & CO. INTERNATIONAL
CITIBANK, N.A.
BURSKI KRZYSZTOF
FOLKES AS
FONDSAVANSE AS
https://photocure.com/investor/largest-shareholders/
Redigert 04.05.2020 kl 11:40
Du må logge inn for å svare
Kom i skade for å skrive at følgende hadde solgt seg ut:
SOCIETE GENERALE214
MORGAN STANLEY & CO. INTERNATIONAL
CITIBANK, N.A.
BURSKI KRZYSZTOF
FOLKES AS
FONDSAVANSE AS
Det er selvsagt ikke nødvendigvis riktig, de har blitt skjøvet ut av topp 50, korrigert tekst i innlegget over.
SOCIETE GENERALE214
MORGAN STANLEY & CO. INTERNATIONAL
CITIBANK, N.A.
BURSKI KRZYSZTOF
FOLKES AS
FONDSAVANSE AS
Det er selvsagt ikke nødvendigvis riktig, de har blitt skjøvet ut av topp 50, korrigert tekst i innlegget over.
Oppdatert Topp 20 gjeldende til og med torsdag i forrige uke.
Største endringer:
SEB + 100k til 530k og opp på 3.plass.
Societe Generale INN til 246k og 18.plass. Økning ukjent, men var UTE av Topp 50 på listen igår(som da gjaldt til og med onsdag)
Societe Generale Paris UT av Topp20.
Totalt antall aksjonærer i Photocure er nå 6869.(var under halvparten for under 1 år siden)
Største endringer:
SEB + 100k til 530k og opp på 3.plass.
Societe Generale INN til 246k og 18.plass. Økning ukjent, men var UTE av Topp 50 på listen igår(som da gjaldt til og med onsdag)
Societe Generale Paris UT av Topp20.
Totalt antall aksjonærer i Photocure er nå 6869.(var under halvparten for under 1 år siden)
Redigert 05.05.2020 kl 10:49
Du må logge inn for å svare
Ny interessant video fra idag, 6.mai.
https://www.youtube.com/watch?v=mtkB4zJOjRg&fbclid=IwAR3GiYEGCU2h-qMFpVYcU6aytpvrDnrqxYYN3FrscZsSiTVndFxwwui-JyE&has_verified=1
https://www.youtube.com/watch?v=mtkB4zJOjRg&fbclid=IwAR3GiYEGCU2h-qMFpVYcU6aytpvrDnrqxYYN3FrscZsSiTVndFxwwui-JyE&has_verified=1
Ny oppdatert Topp 20 liste viser at halvparten av dem har økt siden mandagens liste.(Denne listen gjelder til og med handel mandag inneværende uke)
Avrundet til hele tusen og i rekkefølge etter hvor på Topp 20 dem befinner seg.
3. The Bank of NY Mellon SA/NV +58k
4. SEB Life Intern +100k
5. Nordnet Bank +33k
7. Danske Bank +1k
8. Nordnet Liv +35k
9. Verdipapirfondet FF Norge +14k
14. Verdipapirfondet Pareto Inv. +20k
17. Morgan Stanley & CO.LLC NY med 228k
19. KLP AksjeNorge Indeks + 3k
Societe Generale Paris UT
Avrundet til hele tusen og i rekkefølge etter hvor på Topp 20 dem befinner seg.
3. The Bank of NY Mellon SA/NV +58k
4. SEB Life Intern +100k
5. Nordnet Bank +33k
7. Danske Bank +1k
8. Nordnet Liv +35k
9. Verdipapirfondet FF Norge +14k
14. Verdipapirfondet Pareto Inv. +20k
17. Morgan Stanley & CO.LLC NY med 228k
19. KLP AksjeNorge Indeks + 3k
Societe Generale Paris UT
Redigert 07.05.2020 kl 16:53
Du må logge inn for å svare
NORNE HEVER KURSMÅLET TIL 150!
Even stronger LT growth prospects after Ipsen deal
Type:Result CommentAnbefaling:KjøpKursmål:150
We reiterate Buy recommendation on Photocure share at a higher TP of NOK 150/sh (130) after the news of taking back Hexvix from Ipsen makes it possible for the company to repeat the ongoing US success story in Europe. We see the company’s case strengthened by the news and visibility is better with clear guidance for 2023.
Even stronger LT growth prospects after Ipsen deal
Type:Result CommentAnbefaling:KjøpKursmål:150
We reiterate Buy recommendation on Photocure share at a higher TP of NOK 150/sh (130) after the news of taking back Hexvix from Ipsen makes it possible for the company to repeat the ongoing US success story in Europe. We see the company’s case strengthened by the news and visibility is better with clear guidance for 2023.
-
«
- 1
- 2 »